Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Robbie Stephens Upgrades Visible Gene to 'Strong Buy'

Roberston Stephens boosts Visible Gene (VGIN) to strong buy.

Analyst Edward Tenthoff says he's confirmed from sources that the FDA will require makers of homebrew HIV genotypic resistance tests and suppliers of analyte specific reagents to seek 510(k) regulatory clearance. He expects these companies will have to cease offering HIV resistance testing services, thereby removing all current competition to TruGene HIV resistance assay. Visible Gene could have market exclusivity at launch. Tenthoff thinks the FDA's action will directly impact the company's market share next year. He is confident in his $62 million 2002 TruGene sales forecast, and has a $30 12-month price target.

blog comments powered by Disqus